China+1 for medical devices: Vietnam, Malaysia or Singapore

Medical devices are the quiet but lucrative “China + 1” industry: less noisy than electronics, but with high margins, steady demand growth from ageing populations, and little exposure to trade wars. The three contenders — Vietnam, Malaysia, Singapore — represent three strategies: Vietnam the low-cost workshop, Malaysia the mid-tier manufacturing base (Penang cluster), Singapore the R&D + high-end manufacturing hub. This article scores the three on eight medical-device-specific criteria — an industry where one registration error can get a whole shipment destroyed.

Criteria 1–2: market authorisation and quality systems

(1) Medical-device registration. In Vietnam, Decree 98/2021/ND-CP regulates medical equipment by risk class (A, B, C, D) — classes C and D (high risk: ventilators, stents, implants) require marketing authorisation from the Ministry of Health, with clinical evaluation, testing and ISO 13485 certification in the dossier. Realistic timelines run 6–18 months by class. Singapore’s HSA (Health Sciences Authority) is strict but transparent and predictable — the regional gold standard. Malaysia’s MDA is comparable to Singapore but slower. Scores (procedural predictability): Singapore 9/10, Malaysia 7/10, Vietnam 6/10.

(2) ASEAN harmonisation (AMDD). The ASEAN Medical Device Directive aims at registration harmonisation — but each country keeps its own system with only partial mutual recognition. A plant in Singapore/Malaysia doesn’t automatically sell into Vietnam — Vietnamese authorisation is still required. Practical strategy: pick one “registration hub” (usually Singapore — HSA credibility speeds registrations elsewhere) and manufacture where costs are low. Scores (registration credibility): Singapore 10/10, Malaysia 7/10, Vietnam 6/10.

Criteria 3–4: manufacturing capability and talent

(3) Medical-device clusters. Malaysia: Penang’s decades-old device cluster (gloves, catheters, diagnostics for global brands) — medical plastics, sterilisation and sterile-packaging chains ready. Singapore: high-end, high-value manufacturing (imaging, surgical robots) — not competing on cost. Vietnam: a forming cluster (Bac Ninh, HCMC) — strong in disposables (masks, gloves, syringes), weak in electronic devices. Scores: Malaysia 8/10, Singapore 8/10 (high-end), Vietnam 6/10.

(4) Cleanroom and biomedical talent. Medical devices need ISO class 7/8 cleanrooms, aseptically trained operators and biomedical engineers. Singapore: the best talent but expensive. Malaysia: a good balance — English-speaking engineers, mid-range cost. Vietnam: cheap, trainable operators for disposables; short of experienced biomedical engineers for complex devices. Scores: Malaysia 8/10, Singapore 7/10 (top quality, top price), Vietnam 6/10.

Criteria 5–6: cost and markets

(5) Production cost. Singapore is the region’s priciest — only viable for high-value products (a USD-hundreds-of-thousands imaging machine “carries” Singapore costs; a box of gloves doesn’t). Malaysia: mid-range, right for mid-tier devices. Vietnam: the cheapest — an absolute edge for high-volume disposables. Scores (cost fit): Vietnam 9/10, Malaysia 7/10, Singapore 5/10.

(6) Domestic and export markets. Vietnam: 100 million people, fast-rising health spending, expanding public/private hospitals — double-digit domestic device-market growth. Singapore: a tiny domestic market (6 million) but the regional distribution gateway — HQ in Singapore, sell across ASEAN. Malaysia: 34 million domestic + medical tourism. Scores: Singapore 9/10 (regional gateway), Vietnam 8/10 (domestic growth), Malaysia 7/10.

Criteria 7–8: IP and risk

(7) Intellectual-property protection. Medical devices live on patents: Singapore has Southeast Asia’s strongest IP regime (specialised courts, fast enforcement) — firms site R&D there with confidence. Malaysia: decent. Vietnam: weak enforcement — higher copy risk, better suited to off-patent products (disposables) than proprietary devices. Scores: Singapore 10/10, Malaysia 7/10, Vietnam 5/10.

(8) Supply-chain and geopolitical risk. Medical devices face less US tariff targeting than electronics/furniture — but medical semiconductors still feel chip-export controls. Singapore: neutral, smooth global chains. Malaysia/Vietnam: stable. Scores: Singapore 9/10, Malaysia 8/10, Vietnam 8/10.

Verdict: choose by product “tier”

Totals (out of 80): Singapore 60, Malaysia 60, Vietnam 53 — Singapore and Malaysia tied; Vietnam lower but unbeatable in the low-cost segment. Disposables (gloves, masks, syringes — off-patent, price-competitive) → Vietnam (lowest cost, large domestic market). Mid-tier devices (patient monitors, basic diagnostics, surgical instruments) → Malaysia (Penang cluster, good talent, reasonable cost). High-end devices + R&D (imaging, robots, implants) → Singapore (strong IP, credible HSA, top talent). The big players’ “three-leg” model: R&D + registration in Singapore, mid-tier manufacturing in Malaysia, cheap disposables in Vietnam — each country doing its own “tier”.

Warning: three device-specific traps

(1) “Pending” registrations. Filing in Vietnam then waiting 12 months without word is common — never sign hospital supply contracts before holding the authorisation number; shipping without permission is a violation and goods can be destroyed. (2) Post-approval design changes. Every material/process change after licensing must be notified/reported — many plants “improve” lines and forget to report, and inspections put the licence under review. (3) Sterilisation and batch traceability. Sterile devices need complete per-batch sterilisation records — one faulty batch without traceability triggers a full recall costing dozens of times the batch value. Rule: in medical devices, quality management is the second business licence — losing ISO 13485 means losing everything.

Building the regulatory file before the factory

Sequence matters more in medical devices than in any other “China + 1” industry: start the registration dossier 12–18 months before the plant is ready, because the authorisation timeline is the true critical path, not construction. Hire a regulatory-affairs specialist (not a generalist lawyer) in the manufacturing country from day one — they know which clinical data the reviewers actually accept and which test labs are recognised. For Chinese investors, the winning structure is often “Singapore registration + Vietnam/Malaysia manufacturing”: the HSA-reviewed technical file becomes the master reference that accelerates every subsequent ASEAN filing, while production sits where the cost structure works. Budget USD 200,000–500,000 for the full multi-country registration programme — a fraction of plant capex, but the item most often forgotten until it blocks the first shipment. And keep the design history file immaculate from the first prototype: regulators don’t just review the product, they review how you developed it, and a messy design file is the commonest reason technically sound products get rejected. Tidy the design file before filing — reviewers forgive thin science faster than messy paperwork.

Checklist: siting a medical-device plant

1. Classify the product: disposable, mid-tier or high-end — it decides the location “tier”. 2. Check risk classification (A/B/C/D) in Vietnam and the authorisation roadmap. 3. Assess clusters: Penang (Malaysia), Singapore, or Vietnam’s emerging hubs — medical plastics and sterilisation available? 4. Model cost against product value: do margins “carry” Singapore costs? 5. Check IP: still patented? Where is enforcement strong? 6. Assess cleanroom talent: hired and trained where? 7. Markets: domestic sales or regional export? 8. Prepare registration dossiers before building — never let a finished plant wait for permission to sell. 9. Design batch traceability from day one. 10. Take specialist healthcare legal advice — generalist lawyers aren’t enough in this industry. 11. Start regulatory work 12–18 months before the plant opens; the licence, not the building, is the critical path. 12. Keep a regulatory watch: device classifications and AMDD implementation shift yearly — assign one person to track them, or a rule change can strand a product line overnight. Budget for re-registration costs in the five-year plan — they are inevitable, not exceptional.

Contact us

FLAT Law Firm advises Chinese investors in Vietnam across the full lifecycle: investment structuring, IRC/ERC procedures, tax, labour, intellectual property and dispute resolution. Contact us for advice tailored to your case.

This article has been quality-reviewed by the FLAW AI Legal Council